RE:Anyone want to guess at RBC's new target price?Of course he will. But this is the problem, we have been 100% correct to state that if they have value-enhancing developments about to launch they need to use these to become a more serious player in the serious institutionally-oriented investment community, especially in the US. We all know they have to execute first, but they also have to build a community of serious biotech investors that understand what's going on and how to value it. Part of that is getting on board astute analysts or analyst/firms with large followers just to build interest. Plenty of people will pass on this so you need the largest universe you can build. Maybe they'll come and I am a believer that if you execute properly and the rewards flow, a market will value that properly in time. But if you do that in a vacuum, it's much harder.
And these 3 brokers are non-entities in that field. This gave them zero entre into a larger world of capital markets in the US. The IR ladie's job just got a boatload harder to do in a convincing way. She'll have to wait for clearly facts on the project execution to make any headway in US.
That's the other shame of this deal. If they had "options" like Paul said, they could have continued to interest those "options" as they positively developed the programs and they still would have been around. They played the low odds and costs us all a lot of value.
By the way, on that analogy of selling 30% of the revenue, they sold 30% of the profits, or in this case you could say this money will be paying for all the losses over the next 2-3 years -- all the expenses for the trials. However you look at it they paid what all of us would consider a very high price and missed opportunites if they had been a bit more clever at stringing along all the interested "options" and moved into the summer until they executed this. Rookies....
SPCEO1 wrote: I will guess $1.65.
Of course it will also be interesting to see what changes, if any, Mackie, Canaccord and NBF make too.